T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes.
Saved in:
| Title: | T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. |
|---|---|
| Authors: | Ali M; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Giannakopoulou E; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Li Y; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Lehander M; Department of Medicine, Huddinge Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden., Virding Culleton S; Department of Medicine, Huddinge Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden., Yang W; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Knetter C; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Odabasi MC; Charité - Universitätsmedizin Berlin, Institute of Immunology, Berlin, Germany., Bollineni RC; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Yang X; Parker Institute for Cancer Immunotherapy, Howard Hughes Medical Institute, Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA., Foldvari Z; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Böschen ML; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Taraldsrud E; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Strønen E; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Toebes M; Division of Molecular Oncology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hillen A; Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden., Mazzi S; Department of Medicine, Huddinge Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden., de Ru AH; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands., Janssen GMC; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands., Kolstad A; K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway., Tjønnfjord GE; Department of Haematology, Oslo University Hospital and KG Jebsen Center for B cell malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Lie BA; Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway., Griffioen M; Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands., Lehmann S; Department of Medicine, Huddinge Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.; Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden., Osnes LT; Department of Immunology, Oslo University Hospital, Oslo, Norway., Buechner J; Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway., Garcia KC; Parker Institute for Cancer Immunotherapy, Howard Hughes Medical Institute, Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA., Schumacher TN; Division of Molecular Oncology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, the Netherlands., van Veelen PA; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands., Leisegang M; Charité - Universitätsmedizin Berlin, Institute of Immunology, Berlin, Germany.; David and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, IL, USA.; German Cancer Consortium, partner site Berlin, Berlin, Germany.; German Cancer Research Center, Heidelberg, Germany., Jacobsen SEW; Department of Medicine, Huddinge Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.; Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.; Karolinska University Hospital, Stockholm, Sweden.; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK., Woll P; Department of Medicine, Huddinge Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden., Olweus J; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. johanna.olweus@medisin.uio.no.; K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. johanna.olweus@medisin.uio.no. |
| Source: | Nature biotechnology [Nat Biotechnol] 2022 Apr; Vol. 40 (4), pp. 488-498. Date of Electronic Publication: 2021 Dec 06. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature America Publishing Country of Publication: United States NLM ID: 9604648 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-1696 (Electronic) Linking ISSN: 10870156 NLM ISO Abbreviation: Nat Biotechnol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
